Photo by nci from unsplash
In this small feasibility trial of a next-generation device, the TriGuardHDH embolic protection device (EPD) appears to be safe and feasible during use in the majority of the TAVR subjects… Click to show full abstract
In this small feasibility trial of a next-generation device, the TriGuardHDH embolic protection device (EPD) appears to be safe and feasible during use in the majority of the TAVR subjects studied. The question as to the use of EPD during TAVR, while intuitively appealing, is not further elucidated by the results of this small, uncontrolled study. Future research on this (and other) device(s) would be expected to include, at a minimum, a randomized arm, more standardized imaging, and neurological assessment (including longer-term) protocols, and less variability in valve types used.
Journal Title: Catheterization and Cardiovascular Interventions
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!